These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34440251)

  • 41. Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy.
    de Nigris F; Meo C; Palinski W
    Cells; 2023 Sep; 12(17):. PubMed ID: 37681936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
    Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
    Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
    Rytlewski J; Milhem MM; Monga V
    Ann Transl Med; 2021 Jun; 9(12):1039. PubMed ID: 34277839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.
    Lim J; Poulin NM; Nielsen TO
    Clin Cancer Res; 2015 Nov; 21(21):4753-9. PubMed ID: 26330427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
    Liang J; Chen D; Chen L; She X; Zhang H; Xiao Y
    Future Oncol; 2020 Jun; 16(17):1211-1223. PubMed ID: 32396026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy of Childhood Sarcomas.
    Roberts SS; Chou AJ; Cheung NK
    Front Oncol; 2015; 5():181. PubMed ID: 26301204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Future directions for immunotherapeutic intervention against sarcomas.
    Maki RG
    Curr Opin Oncol; 2006 Jul; 18(4):363-8. PubMed ID: 16721132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional.
    Borgatti A; Dickerson EB; Lawrence J
    Vet Comp Oncol; 2020 Mar; 18(1):9-24. PubMed ID: 31749286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential for immunotherapy in soft tissue sarcoma.
    Tseng WW; Somaiah N; Engleman EG
    Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches.
    Koumarianou A; Duran-Moreno J
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer Immunotherapy: Beyond Checkpoint Blockade.
    Dougan M; Dranoff G; Dougan SK
    Annu Rev Cancer Biol; 2019 Mar; 3():55-75. PubMed ID: 37539076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances and application of PD-1 blockade in sarcoma.
    Zuo W; Zhao L
    Onco Targets Ther; 2019; 12():6887-6896. PubMed ID: 31692518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is immunotherapy in the future of therapeutic management of sarcomas?
    Clemente O; Ottaiano A; Di Lorenzo G; Bracigliano A; Lamia S; Cannella L; Pizzolorusso A; Di Marzo M; Santorsola M; De Chiara A; Fazioli F; Tafuto S
    J Transl Med; 2021 Apr; 19(1):173. PubMed ID: 33902630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer.
    Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.